FFTY:NYE-Innovator IBD® 50 ETF (USD)

ETF | Mid-Cap Growth |

Last Closing

USD 27.11

Change

+0.59 (+2.22)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Mid-Cap Growth

Symbol Name Price(Change) Market Cap
IWP iShares Russell Mid-Cap Growth..

+1.41 (+1.21%)

USD 14.94B
VOT Vanguard Mid-Cap Growth Index ..

+2.25 (+0.93%)

USD 14.12B
IJK iShares S&P Mid-Cap 400 Growth..

+0.80 (+0.88%)

USD 9.35B
XMMO Invesco S&P MidCap Momentum ET..

+1.38 (+1.15%)

USD 2.45B
IVOG Vanguard S&P Mid-Cap 400 Growt..

+1.02 (+0.90%)

USD 1.08B
ETHO Amplify ETF Trust

+0.65 (+1.11%)

USD 0.18B
CWS AdvisorShares Focused Equity E..

+0.23 (+0.34%)

USD 0.17B
IPO Renaissance IPO ETF

+0.58 (+1.39%)

USD 0.15B
BFOR Barron's 400 ETF

+1.00 (+1.41%)

USD 0.15B
PEXL Pacer US Export Leaders ETF

+0.62 (+1.25%)

USD 0.07B

ETFs Containing FFTY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Mid-Cap Growth) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.24% 31% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.24% 31% F 51% F
Trailing 12 Months  
Capital Gain 20.54% 33% F 54% F
Dividend Return 0.70% 44% F 7% C-
Total Return 21.24% 22% F 47% F
Trailing 5 Years  
Capital Gain -16.74% 11% F 25% F
Dividend Return 2.63% 33% F 8% B-
Total Return -14.11% 11% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -1.86% N/A N/A 27% F
Dividend Return -1.20% N/A N/A 18% F
Total Return 0.66% N/A N/A 16% F
Risk Return Profile  
Volatility (Standard Deviation) 29.56% N/A N/A 35% F
Risk Adjusted Return -4.05% N/A N/A 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike